TABLE 3.
Univariate regression models of entire study cohort
| Non-relapse mortality | Relapse | Relapse-free survival | Overall survival | |
|---|---|---|---|---|
| TRM score (continuous) | 1.12 (1.10–1.15), P<0.001 | 1.07 (1.04–1.10), P<0.001 | 1.09 (1.08–1.11), P<0.001 | 1.11 (1.09–1.14), P<0.001 |
| TRM score (by quartiles) | ||||
| 1st quartile (n=215) | 1 (Reference) | 1 (Reference) | 1 (Reference) | 1 (Reference) |
| 2nd quartile (n=215) | 1.71 (1.03–2.84), P=0.040 | 1.12 (0.78–1.60), P=0.54 | 1.29 (0.96–1.72), P=0.087 | 1.29 (0.95–1.75), P=0.10 |
| 3rd quartile (n=216) | 2.59 (1.58–4.25), P<0.001 | 1.64 (1.17–2.30), P=0.004 | 1.92 (1.46–2.54), P<0.001 | 1.85 (1.38–2.48), P<0.001 |
| 4th quartile (n=215) | 4.33 (2.71–6.90), P<0.001 | 1.87 (1.34–2.62), P<0.001 | 2.56 (1.96–3.36), P<0.001 | 2.66 (2.00–3.53), P<0.001 |
| PAM score | ||||
| <17 (n=449) | 1 (Reference) | 1 (Reference) | 1 (Reference) | 1 (Reference) |
| 17–23 (n=274) | 2.00 (1.45–2.76), P<0.001 | 1.62 (1.24–2.12), P<0.001 | 1.77 (1.44–2.17), P<0.001 | 1.82 (1.47–2.26), P<0.001 |
| 24–30 (n=72) | 2.34 (1.38–3.96), P=0.0016 | 2.87 (1.99–4.13), P<0.001 | 2.68 (1.99–3.62), P<0.001 | 2.55 (1.85–3.50), P<0.001 |
| >30 (n=17) | 3.38 (1.36–8.37), P=0.0086 | 2.84 (1.39–5.82), P=0.0043 | 3.03 (1.73–5.32), P<0.001 | 3.42 (1.94–6.02), P<0.001 |
| HCT-CI/Age Composite score | ||||
| 0 (n=27) | 1 (Reference) | 1 (Reference) | 1 (Reference) | 1 (Reference) |
| 1–2 (n=263) | 1.76 (0.55–5.66), P=0.34 | 0.96 (0.50–1.86), P=0.91 | 1.15 (0.65–2.03), P=0.63 | 1.09 (0.60–1.97), P=0.78 |
| 3–4 (n=313) | 2.19 (0.69–6.99), P=0.16 | 1.02 (0.53–1.95), P=0.96 | 1.29 (0.73–2.27), P=0.38 | 1.23 (0.68–2.21), P=0.49 |
| ≥5 (n=258) | 3.26 (1.02–10.36), P=0.045 | 1.02 (0.57–2.10), P=0.79 | 1.58 (0.90–2.78), P=0.11 | 1.55 (0.86–2.79), P=0.15 |
| Age at HCT | 1.03 (1.02–1.04), P<0.001 | 1.01 (1.00–1.02), P=0.038 | 1.02 (1.01–1.02), P<0.001 | 1.02 (1.01–1.02), P<0.001 |
| Gender | ||||
| Female (n=387) | 1 (Reference) | 1 (Reference) | 1 (Reference) | 1 (Reference) |
| Male (n=464) | 1.47 (1.09–1.98), P=0.012 | 1.14 (0.90–1.44), P=0.29 | 1.25 (1.04–1.51), P=0.017 | 1.23 (1.01–1.49), P=0.038 |
| Cytogenetic risk | ||||
| Favorable/intermediate (n=613) | 1 (Reference) | 1 (Reference) | 1 (Reference) | 1 (Reference) |
| Adverse (n=213) | 0.70 (0.47–1.04), P=0.075 | 1.99 (1.56–2.56), P<0.001 | 1.40 (1.14–1.72), P=0.0012 | 1.27 (1.02–1.57), P=0.032 |
| Type of AML | ||||
| De novo (n=628) | 1 (Reference) | 1 (Reference) | 1 (Reference) | 1 (Reference) |
| Secondary (n=233) | 1.40 (1.03–1.91), P=0.033 | 1.13 (0.88–1.47), P=0.34 | 1.23 (1.01–1.50), P=0.037 | 1.22 (0.99–1.51), P=0.056 |
| Disease status | ||||
| First remission (n=653) | 1 (Reference) | 1 (Reference) | 1 (Reference) | 1 (Reference) |
| Second remission (n=208) | 1.35 (0.97–1.88), P=0.074 | 1.44 (1.11–1.87), P=0.0055 | 1.41 (1.15–1.72), P=0.001 | 1.48 (1.20–1.83), P<0.001 |
| Pre-HCT MRD status | ||||
| MRDneg (n=690) | 1 (Reference) | 1 (Reference) | 1 (Reference) | 1 (Reference) |
| MRDpos (n=171) | 1.48 (1.00–2.20), P=0.051 | 4.18 (3.28–5.32), P<0.001 | 2.99 (2.44–3.65), P<0.001 | 2.44 (1.98–3.01), P<0.001 |
| Pre-HCT karyotype | ||||
| Normalized (n=343) | 1 (Reference) | 1 (Reference) | 1 (Reference) | 1 (Reference) |
| Not normalized (n=135 | 1.62 (1.03–2.55), P=0.035 | 2.29 (1.69–3.11), P<0.001 | 2.06 (1.60–2.65), P<0.001 | 1.92 (1.48–2.51), P<0.001 |
| Pre-HCT ANC * | ||||
| Recovered (n=801) | 1 (Reference) | 1 (Reference) | 1 (Reference) | 1 (Reference) |
| Not recovered (n=60) | 1.76 (1.04–2.99), P=0.037 | 1.90 (1.29–2.81), P=0.0013 | 1.85 (1.35–2.54), P<0.001 | 1.90 (1.37–2.64), P<0.001 |
| Pre-HCT platelet count * | ||||
| Recovered (n=624) | 1 (Reference) | 1 (Reference) | 1 (Reference) | 1 (Reference) |
| Not recovered (n=237) | 1.74 (1.28–2.36), P<0.001 | 1.08 (0.83–1.41), P=0.54 | 1.31 (1.07–1.60), P=0.0077 | 1.37 (1.12–1.69), P=0.0026 |
| Pre-HCT blood counts * | ||||
| Recovered (n=618) | 1 (Reference) | 1 (Reference) | 1 (Reference) | 1 (Reference) |
| Not recovered (n=243) | 1.72 (1.27–2.34), P<0.001 | 1.10 (0.85–1.43), P=0.46 | 1.32 (1.08–1.60), P=0.0061 | 1.39 (1.13–1.71), P=0.0015 |
| Donor | ||||
| Related (n=243) | 1 (Reference) | 1 (Reference) | 1 (Reference) | 1 (Reference) |
| Unrelated (n=618) | 1.36 (0.97–1.88), P=0.074 | 0.92 (0.72–1.19), P=0.53 | 1.07 (0.87–1.31), P=0.53 | 1.14 (0.92–1.41), P=0.24 |
| Stem cell source | ||||
| PB (n=662) | 1 (Reference) | 1 (Reference) | 1 (Reference) | 1 (Reference) |
| BM (n=74) | 0.54 (0.28–1.06), P=0.074 | 1.31 (0.90–1.89), P=0.16 | 1.00 (0.72–1.38), P=0.99 | 0.95 (0.68–1.34), P=0.79 |
| UCB (n=125) | 1.09 (0.73–1.64), P=0.67 | 0.83 (0.58–1.20), P=0.32 | 0.93 (0.71–1.22), P=0.61 | 1.02 (0.77–1.35), P=0.90 |
| HLA matching | ||||
| 10/10 HLA-identical related donor (n=211) | 1 (Reference) | 1 (Reference) | 1 (Reference) | 1 (Reference) |
| 10/10 HLA-matched unrelated donor (n=409) | 1.15 (0.77–1.70), P=0.49 | 1.03 (0.77–1.37), P=0.85 | 1.07 (0.85–1.35), P=0.55 | 1.08 (0.85–1.38), P=0.53 |
| 9/10 HLA-matched unrelated donor (n=90) | 2.63 (1.66–4.19), P<0.001 | 1.22 (0.81–1.86), P=0.34 | 1.70 (1.25–2.30), P<0.001 | 1.88 (1.37–2.59), P<0.001 |
| HLA-haploidentical donor (n=26) | 2.05 (0.86–4.86), P=0.10 | 2.08 (1.17–3.70), P=0.012 | 2.10 (1.30–3.38), P=0.0024 | 2.00 (1.19–3.34), P=0.0086 |
| UCB (n=125) | 1.47 (0.90–2.40), P=0.10 | 0.86 (0.57–1.31), P=0.49 | 1.07 (0.78–1.47), P=0.67 | 1.19 (0.86–1.65), P=0.29 |
| Year of HCT | ||||
| 2006–2012 (n=397) | 1 (Reference) | 1 (Reference) | 1 (Reference) | 1 (Reference) |
| 2013–2019 (n=464) | 1.06 (0.78–1.45), P=0.70 | 0.75 (0.59–0.95), P=0.017 | 0.88 (0.72–1.07), P=0.20 | 0.85 (0.71–1.03), P=0.095 |
Results are presented as hazard radio (95% confidence interval), and P-value;
*
Recovered: ANC ≥1,000/μL and platelets ≥100,000/μL; not recovered: ANC <1,000/μL and/or platelets <100,000/μL.
Abbreviations: ANC, absolute neutrophil count; BM, bone marrow; HCT, hematopoietic cell transplantation; MAC, myeloablative conditioning; MRD, measurable residual disease; PB, peripheral blood; UBC, umbilical cord blood; WBC, total white blood cell count.